Watch CNBX. Know when insiders buy.
One email the day a filing lands. Free.
CNBX
CNBX Pharmaceuticals Inc.
0.00
+0.00 +0.00%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
79
PASS · shorts 79
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $161KP/E —DIV YIELD —FCF YIELD —REV TTM $0NET INCOME −$462KNET CASH —52W 0.00 – 0.00SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · May 31 | $0 | — | — | −$163K | −$154K | — | 0.00 | −$48K | — | — | Jun 24 |
| Q2 2026 · Feb 28 | $0 | — | — | −$73K | −$44K | — | 0.00 | −$31K | — | — | Apr 14 |
| Q1 2026 · Nov 30 | $0 | — | — | −$64K | −$114K | — | 0.00 | −$47K | — | — | Jan 14 |
| Q4 2025 · Aug 31derived | $0 | — | — | −$130K | −$150K | — | 0.00 | −$29K | — | — | Dec 1 |
| Q3 2025 · May 31 | $0 | — | — | −$40K | −$60K | — | 0.00 | −$52K | — | — | Jun 24 |
| Q2 2025 · Feb 28 | $0 | −100.0% | — | −$65K | −$70K | — | 0.00 | −$52K | — | — | Apr 14 |
| Q1 2025 · Nov 30 | $0 | −100.0% | — | −$37K | −$34K | — | -0.00 | −$39K | — | — | Jan 14 |
| Q4 2024 · Aug 31derived | $0 | −100.0% | — | −$53K | −$61K | — | 0.00 | −$48K | — | — | Dec 1 |
| Q3 2024 · May 31 | $0 | — | — | −$152K | −$131K | — | 0.00 | $225 | — | — | Jul 14 |
| Q2 2024 · Feb 29 | $41K | — | 84.7% | −$206K | −$325K | — | -0.01 | −$124K | — | — | Apr 14 |
| Q1 2024 · Nov 30 | $89K | — | — | −$172K | −$179K | — | -0.01 | −$72K | — | — | Jan 13 |
| Q4 2023 · Aug 31derived | $100K | — | — | −$161K | −$574K | — | 0.36 | $21K | — | — | Nov 29 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Aug 31 | $0 | — | −$272K | −$314K | — | 0.00 | −$171K | — | — | — | — |
| FY2024 · to Aug 31 | $130K | — | −$583K | −$695K | -534.5% | -0.02 | −$244K | — | — | — | — |
| FY2023 · to Aug 31 | $410K | — | −$931K | −$3.7M | -904.6% | -0.42 | −$113K | — | — | — | — |
| FY2022 · to Aug 31 | $30K | — | −$3M | −$3.7M | -12428.2% | -3.59 | −$1.7M | — | — | — | — |
| FY2021 · to Aug 31 | $0 | — | −$2.6M | −$3.2M | — | -0.02 | −$2.5M | — | — | — | — |
| FY2020 · to Aug 31 | $7K | — | −$3M | −$7.5M | -104337.9% | -0.10 | −$2.8M | — | — | — | — |
Every number comes from CNBX Pharmaceuticals Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.